Revenue
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Plc (HEMO)
Price£5.20Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 | £0 | £0 |
| Operating expenses | £3.7M | £4.4M | £3.9M | £3.3M | — | — |
| Operating income | −£4.7M | £5.4M | £6.5M | −£4.0M | −£2.7M | −£2.2M |
| EBITDA | −£8.9M | £6.0M | £7.1M | −£3.4M | −£2.6M | −£2.0M |
| Net income | −£9.8M | −£5.6M | −£6.7M | −£4.0M | −£5.1M | −£2.1M |
| Basic EPSper basic share | -£1.71 | -£0.02 | -£0.02 | £0.01 | £0.01 | £0.01 |
| Diluted EPSper diluted share | -£1.71 | -£0.02 | -£0.02 | £0.01 | £0.01 | £0.01 |